Resumo

TEJEDOR-TEJADA, E; MARTINEZ-VELASCO, E; JURADO-HERRERA, S  e  GOMEZ-NUNEZ, MR. Midostaurin in combination with chemotherapy as a treatment for acute myeloblastic leukemia with FTL3 mutation, a case report. Rev. OFIL·ILAPHAR [online]. 2022, vol.32, n.3, pp.295-297.  Epub 25-Set-2023. ISSN 1699-714X.  https://dx.doi.org/10.4321/s1699-714x20220003000014.

Acute myeloblastic leukemia (AML) is a heterogeneous disease characterized by uncontrolled growth of undifferentiated myeloid precursors leading to bone marrow failure. According to data from the Surveillance, Epidemiology and End Results (SEER) program, the annual incidence is estimated at 4.2 per 100,000 population. The incidence rate in children under 20 years of age is 5.1% and in people between 65-84 years of age, it is 46.5%. The 5-year survival rate varies according to the age of the patients, being 67% in those under 20 years of age and 25% in those older than 20 years of age. Acute myeloid leukemia represents 40% of all leukemias and the median age of the patients is 65 years. The most frequent cytogenetic alterations are: translocation (8;21), inversion of chromosome 16, translocation (16;16), trisomy of chromosome 8 and deletions in chromosomes 5 and 7, mutation in the FLT3 gene (13q12), which is present in 30% of new diagnoses. Standard chemotherapy treatment is still based on the intensive 3+7 scheme consisting of cytarabine with anthracyclines. The focus of new therapies in AML is targeted therapy due to advances in diagnosis and typing.

Palavras-chave : Midostaurin; acute myeloid leukemia; personalized treatment.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )